| Literature DB >> 33118412 |
Silvie Grote1, Jeanette M Ricci2, Salem Dehom3, Naomi Modeste3, Diadrey-Ann Sealy4, Heather P Tarleton5.
Abstract
Cardiotoxicity as a result of cancer treatment contributes to autonomic dysfunction and decreased cardiorespiratory fitness among cancer survivors. These deleterious cardiovascular outcomes reduce the survival prognosis for cancer patients and contribute to poor quality of life among survivors. Exercise interventions have been shown as effective in mitigating treatment-related side effects. However, previously published interventions have not explored the potential for improvement in autonomic dysfunction (heart rate variability, HRV). This study examined cardiovascular adaptations in cancer survivors (n = 76) who participated in a 26-week intervention consisting of combined aerobic and resistance training (CART). The most noteworthy improvements occurred during the first 13 weeks of training and were maintained throughout the end of the 26-week period. HRrest improved from baseline (PRE) to the midpoint (MID) (P = .036) and from PRE to POST timepoints (P = .029). HRV and VO2max did not initially appear to change in response to CART. However, after stratification on time since treatment, participants who were 5 or more years from their last treatment experienced improvements (ie increase) in the HRV characteristic of HF power (P = .050) and also in VO2max (P =.043), when compared to those experiencing less than 5 years of time since their last treatment. These findings highlight a need for more attention to address the cardiorespiratory deficits experienced by those who have recently completed cancer treatment. In conclusion, the CART intervention is effective in improving cardiorespiratory fitness and autonomic dysfunction. The structure of the intervention is feasible for cancer survivors to continue with at home, using minimal resources, and without supervision. This at-home model may be even more acceptable to recent survivors that may be homebound immediately following treatment.Entities:
Keywords: cancer survivorship; cardiotoxicity; cardiovascular fitness; combined aerobic and resistance training; heart rate variability
Year: 2020 PMID: 33118412 PMCID: PMC7605052 DOI: 10.1177/1534735420969816
Source DB: PubMed Journal: Integr Cancer Ther ISSN: 1534-7354 Impact factor: 3.279
Participant Characteristics at Baseline for the IMPAACT Study (n = 76).
| Item | Category |
| % of sample |
|---|---|---|---|
| Gender | Men | 7 | 9.2 |
| Women | 69 | 90.8 | |
| Race | White | 49 | 64.5 |
| Non-White | 27 | 35.5 | |
| Time since treatment (TST) | <5 years | 36 | 52.2 |
| ≥5 years | 33 | 47.8 | |
| Treatment type | Surgery/other | 25 | 32.9 |
| Chemotherapy/radiation | 51 | 67.1 | |
| Smoking status | Never smoked >100 cigarettes or other tobacco products | 51 | 69.9 |
| Other | 22 | 30.1 | |
| Education | Some college or less | 18 | 24.0 |
| College graduate | 57 | 76.0 | |
| Sleep/night | 4 or less hours | 1 | 1.3 |
| 5-6 hours | 43 | 57.3 | |
| 7 or more hours | 31 | 41.3 | |
| Perceived physical activity | Good/OK | 30 | 40.0 |
| Needs improvement | 45 | 60.0 |
P < .05 between category groups.
Sample size is varied due to incomplete survey data.
Change in Outcome Measures at Baseline, 13 weeks, and 26 weeks of an Exercise Intervention in Cancer Survivors.
| Outcome measures | PRE |
| MID |
| POST | n |
|---|---|---|---|---|---|---|
| (0 weeks) | (13 weeks) | (26 weeks) | ||||
| HRrest (bpm) | 71.1 (67.1, 75.3) | 76 | 65.1 (62.1, 67.6) | 63 | 64.8 (62.3, 67.5) | 53 |
| VO2max (mL/kg/min) | 22.2 (20.0, 24.5) | 69 | 21.5 (19.2, 24.0) | 57 | 21.3 (18.8, 24.0) | 47 |
| Low frequency (LF) power (ms2)[ | 269.4 (192.8, 376.5) | 62 | 228.5 (162.6, 321.1) | 60 | 203.1 (137.7, 299.5) | 46 |
| High frequency (HF) power (ms2)[ | 187.6 (125.4, 280.7) | 62 | 196.1 (130.2, 295.4) | 60 | 174.4 (109.2, 278.5) | 46 |
| LF/HF Power (ms2)[ | 1.4 (1.1, 1.8) | 62 | 1.1 (0.9, 1.4) | 60 | 1.1 (0.8, 1.5) | 46 |
Data reported as mean (95% Confidence Interval): bpm = beats per minute. Sample size may vary due to the inability of a small number of participants to complete the assessment battery.
Based on log transformed variable.
Significant difference between PRE and MID and PRE and POST (P < .05).
Figure 1.Percent of participants experiencing a reduction in resting heart rate (HRrest) from baseline (PRE) to 13 weeks (MID), from MID to 26 weeks (POST), and from PRE to POST for participants attending ≤50% of sessions compared to participants attending >50% of sessions.
Figure 2.Percent of participants who demonstrated improvement in outcome measures from baseline (PRE) to 13 weeks (MID) for participants within 5 years of treatment (TST < 5 years) compared to participants who received their last treatment 5 or more years prior to study onset (TST ≥ 5 years).